

Please check our [wiki](#) for help on navigating the form.

## Horizon 2020

**Call: H2020-SC1-BHC-2018-2020**

(Better Health and care, economic growth and sustainable health systems)

**Topic: SC1-BHC-18-2018**

**Type of action: RIA**

**Proposal number: SEP-210512885**

**Proposal acronym: SELNET**

**Deadline Id: H2020-SC1-2018-Single-Stage-RTD**

### Table of contents

Section	Title	Action
1	General information	
2	Participants & contacts	
3	Budget	
4	Ethics	
5	Call-specific questions	

#### *How to fill in the forms*

The administrative forms must be filled in for each proposal using the templates available in the submission system. Some data fields in the administrative forms are pre-filled based on the steps in the submission wizard.

# Proposal Submission Forms

Proposal ID SEP-210512885

Acronym SELNET

## 1 - General information

Topic SC1-BHC-18-2018

Type of Action RIA

Call Identifier H2020-SC1-BHC-2018-2020

Deadline Id H2020-SC1-2018-Single-Stage-RTD

Acronym SELNET

Proposal title Sarcoma as a model to improve diagnosis and clinical care of rare tumors through a European and Latin American multidisciplinary network

Note that for technical reasons, the following characters are not accepted in the Proposal Title and will be removed: < > " &

Duration in months 48

Fixed keyword 1 Cancer and its biological basis

Free keywords Sarcoma ;diagnosis; clinical care; rare tumors; prognosis

### Abstract

Rare cancersRare cancers are associated with poor survival, accounting for 22% of new cancer diagnoses in Europe, and 30% of cancer deaths. Sarcomas are a heterogeneous group of life-threatening rare solid malignancies affecting soft and bone tissues, representing 10% of rare tumors and around 2% of adult tumors, with an incidence of 5.9/100,000/year in Europe. Appropriate management of sarcoma patients is hindered by the absence of referral policies to reference centers (RCs), incorrect or delayed diagnosis, non-adherence of therapies to clinical practice guidelines (CPGs), and lack of expertise by practitioners, which increases the risk of relapse and death. These problems worsen in the Community of Latin American and Caribbean States (CELAC) due to the scarcity or complete unavailability of RCs, expert pathologists, multidisciplinary tumor boards (MTBs), new cancer drugs, clinical trials, patient registry data, and financial resources. Hence, the SELNET project seeks to create a European and Latin American multidisciplinary network of clinical and translational specialists to improve diagnosis and clinical care in sarcomas, with the aim of validating a collaborative model replicable in other rare tumors and in other countries. Recognized cancer centers and research groups of Spain, Italy, France, Mexico, Brazil, Argentina, Costa Rica, and Peru will contribute to better rare cancer care by fostering RCs, healthcare barrier analysis, CPGs, and medical education as key improvement drivers. The core of the research work focuses on improving diagnosis and prognosis of sarcoma patients through the creation of pathological diagnosis networks, MTBs, the conduct of an international registry-based observational study to assess clinical management quality and prognostic factors, and the implementation of an strategic translational research program to develop intercontinental sarcoma biobanks, preclinical models, and a translational study with drugs in rare sarcoma subtypes.

Remaining characters

0

Has this proposal (or a very similar one) been submitted in the past 2 years in response to a call for proposals under Horizon 2020 or any other EU programme(s)?

Yes  No

Please give the proposal reference or contract number.

xxxxxx-x

# Proposal Submission Forms

Proposal ID: **SEP-210512885**

Acronym: **SELNET**

## 2 - Participants & contacts

#	Participant Legal Name	Country	Action
1	SERVICIO ANDALUZ DE SALUD	Spain	
2	FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI	Italy	
3	ISTITUTO ORTOPEDICO RIZZOLI	Italy	
4	CENTRE ANTICANCEREUX LEON BERARD	France	
5	Instituto Nacional de Cancerología	Mexico	
6	Centro Médico Nacional 20 de Noviembre	Mexico	
7	A.C.Camargo Cancer Center	Brazil	
8	Instituto Alexander Fleming	Argentina	
9	Hospital San Vicente de Paúl	Costa Rica	
10	Instituto Nacional de Enfermedades Neoplásicas	Peru	
11	GRUPO ESPANOL DE INVESTIGACION EN SARCOMAS ASOCIACION	Spain	
12	SARCOMA PATIENTS EURONET EV	Germany	



**Table 3.4b: Otros artículos de costo directo (viajes, equipo, otros bienes y servicios, gran infraestructura de investigación)**

<b>10/INE</b>	<b>Costo (€)</b>	<b>Justificación</b>
<b>Viajes</b>	19,000	Reuniones nacionales e internacionales.
<b>Equipo</b>		
<b>Otros bienes y servicios.</b>	7,460	Honorarios éticos y regulatorios, PC, Internet de alta velocidad, sistema de teleconferencia
<b>Total</b>	<b>26,460</b>	

# Proposal Submission Forms

Proposal ID SEP-210512885

Acronym SELNET

Short name INST. NAC. ENFER. NEOPLASICAS

PIC 906217360  
Legal name Instituto Nacional de Enfermedades Neoplásicas

Short name: INST. NAC. ENFER. NEOPLASICAS

## Address of the organisation

Street Av. Angamos Este 2520 - Surquillo  
Town Lima  
Postcode 15038  
Country Peru  
Webpage <http://portal.inen.sld.pe>

## Legal Status of your organisation

### Research and Innovation legal statuses

Public body	unknown	Legal person	yes
Non-profit	unknown		
International organisation	unknown		
International organisation of European interest	unknown		
Secondary or Higher education establishment	unknown	Industry (private for profit)	unknown
Research organisation	unknown		

### Enterprise Data

SME self-declared status unknown  
SME self-assessment unknown  
SME validation sme unknown

Based on the above details of the Beneficiary Registry the organisation is not an SME (small and medium-sized enterprise) for the call.



# Proposal Submission Forms

Proposal ID SEP-210512885

Acronym SELNET

Short name INST. NAC. ENFER. NEOPLASICAS

## Department(s) carrying out the proposed work

### Department 1

Department name Oncology

not applicable

Same as proposing organisation's address

Street Av. Angamos Este 2520 - Surquillo

Town Lima

Postcode 15038

Country Peru

## Dependencies with other proposal participants

Character of dependence	Participant	

# Proposal Submission Forms

Proposal ID SEP-210512885

Acronym SELNET

Short name INST. NAC. ENFER. NEOPLASICAS

## Person in charge of the proposal

The name and e-mail of contact persons are read-only in the administrative form, only additional details can be edited here. To give access rights and basic contact details of contact persons, please go back to Step 4 of the submission wizard and save the changes.

Title

Sex  Male  Female

First name Victor

Last name Castro Oliden

E-Mail vcastrooliden@gmail.com

Position in org.

Department

Same as organisation name

Same as proposing organisation's address

Street

Town

Post code

Country

Website

Phone

Phone 2

Fax



### 3 - Budget

No.	Participant	Country	(A) Direct personnel costs/€	(B) Other direct costs/€	(C) Direct costs of subcontracting/€	(D) Direct costs of providing financial support to third parties/€	(E) Costs of kind contributions not used on the beneficiary's premises/€	(F) Indirect Costs /-€ (=0.25*(A+B-E))	(G) Special unit costs covering direct & indirect costs / €	(H) Total estimated eligible costs (=A+B+C+D+F+G)	(I) Reimbursement rate (%)	(J) Max EU Contribution/€ (=H*I)	(K) Requested EU Contribution/€
1	Servicio Andaluz De Salud	ES	475200	158400	0	0	0	158400,00	0	792000,00	100	792000,00	792000,00
2	Fondazione Ircs Istituto Nazionale Dei Istituti	IT	315000	45000	0	0	0	90000,00	0	450000,00	100	450000,00	450000,00
3	Ortopedico Rizzoli	IT	319680	25920	0	0	0	86400,00	0	432000,00	100	432000,00	432000,00
4	Centre Anticancereux Leon Berard	FR	340200	48600	0	0	0	97200,00	0	486000,00	100	486000,00	486000,00
5	Instituto Nacional De Cancerologia	MX	97200	32400	0	0	0	32400,00	0	162000,00	100	162000,00	162000,00
6	Centro Médico Nacional 20 De Noviembre	MX	86400	28800	0	0	0	28800,00	0	144000,00	100	144000,00	144000,00
7	A. c. camargo Cancer Center	BR	131040	30240	0	0	0	40320,00	0	201600,00	100	201600,00	201600,00
8	Instituto Alexander Fleming	AR	116640	38880	0	0	0	38880,00	0	194400,00	100	194400,00	194400,00
9	Hospital Vicente De Paul	CR	117000	27000	0	0	0	36000,00	0	180000,00	100	180000,00	180000,00
10	Instituto Nacional De Enfermedades	PE	114660	26460	0	0	0	35280,00	0	176400,00	100	176400,00	176400,00



3/IOR	Cost (€)	Justification
Travel	19,000	National and international meetings
Equipment		
Other goods and services	6,920	Audit certificate
<b>Total</b>	<b>25,920</b>	

4/CLB	Cost (€)	Justification
Travel	28,000	National and international meetings
Equipment		
Other goods and services	20,600	Lab kits, audit certificate
<b>Total</b>	<b>48,600</b>	

5/INC	Cost (€)	Justification
Travel	19,000	National and international meetings
Equipment		
Other goods and services	13,400	Ethics and regulatory fees, PC, high-speed Internet, teleconference system
<b>Total</b>	<b>32,400</b>	

6/CMN	Cost (€)	Justification
Travel	18,000	National and international meetings
Equipment		
Other goods and services	10,800	Ethics and regulatory fees, PC, high-speed Internet, teleconference system
<b>Total</b>	<b>28,800</b>	

7/CCC	Cost (€)	Justification
Travel	19,000	National and international meetings
Equipment		
Other goods and services	11,240	Ethics and regulatory fees, PC, high-speed Internet, teleconference system
<b>Total</b>	<b>30,240</b>	

8/IAF	Cost (€)	Justification
Travel	19,000	National and international meetings
Equipment		
Other goods and services	19,880	Ethics and regulatory fees, PC, high-speed Internet, teleconference system
<b>Total</b>	<b>38,880</b>	

9/HSV	Cost (€)	Justification
Travel	18,000	National and international meetings
Equipment		
Other goods and services	9,000	Ethics and regulatory fees, PC, high-speed Internet, teleconference system
<b>Total</b>	<b>27,000</b>	

10/INE	Cost (€)	Justification
Travel	19,000	National and international meetings
Equipment		
Other goods and services	7,460	Ethics and regulatory fees. PC. high-speed Internet. teleconference system
<b>Total</b>	<b>26,460</b>	

**JOSÉ CAÑÓN CAMPOS, EN CALIDAD DE DIRECTOR GERENTE DE LA FUNDACIÓN  
PÚBLICA ANDALUZA PARA LA GESTIÓN DE LA INVESTIGACIÓN EN SALUD DE  
SEVILLA**

**CERTIFICA**

que, con fecha 05/02/2019 se ha procedido mediante transferencia bancaria al ingreso del importe de 85.260€ euros al INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS-INEN en la cuenta bancaria indicada por dicho centro a tal efecto. Este importe corresponde al pre-funding del centro para su participación en el proyecto detallado a continuación

Acronym: SELNET

Title: Sarcoma as a model to improve diagnosis and clinical care of rare tumors through a European and Latin American multidisciplinary network

Grant Agreement no.: 825806

Call/Topic: Translational collaborative cancer research between Europe and the Community of Latin American and Caribbean States (CELAC)

Lead coordinator: Servicio Andaluz de Salud - Investigador Principal: Dr. Javier Martin Broto-Hospital Virgen del Rocío).

Se adjunta como Anexo al presente certificado el documento resumido con los datos principales del Acuerdo de subvención firmado con la Comisión Europea en el que consta el importe total del presupuesto del centro ("GRANT AGREEMENT DATA SHEET").

Se adjunta además la página 34 del Acuerdo de Subvención en el que se recoge el importe recibido por el Coordinador de la Comisión Europea en concepto de pre-funding, que ha sido de 1.649.280,00€, equivalente al 53,33% del presupuesto total. Siguiendo el Grant Agreement y las normas de financiación de la Comisión Europea, se procede a la retención del 5% para el fondo de garantía ("Guarantee Fund" - dicho importe podrá ser devuelto a la finalización del proyecto).

Se especifica que el ingreso realizado por el Coordinador a cada socio del proyecto ha sido proporcional a estos porcentajes. En el caso de INEN, el presupuesto total es de 176.400€, y el ingreso realizado en concepto de pre-funding de 85.260,00€.



**José Cañón Campos**  
Director Gerente



EUROPEAN COMMISSION  
DIRECTORATE-GENERAL RESEARCH & INNOVATION  
Non-communicable diseases and the challenge of healthy ageing



**GRANT AGREEMENT DATA SHEET**

Grant Agreement (GA) No: 825806

Acronym: SELNET

Title: Sarcoma as a model to improve diagnosis and clinical care of rare tumors through a European and Latin American multidisciplinary network

Call/Topic: Translational collaborative cancer research between Europe and the Community of Latin American and Caribbean States (CELAC)

Type of action: Research and Innovation action

Granted by: European Union

Consortium agreement required: Yes

Collaboration agreement required: No

Coordination agreement required: No

Duration (in months): 48

Starting Date: 1 January 2019

Justification: Start date on 1 January 2019 as agreed with EC services.

End date: 31 December 2022

Reimbursement rate: 100% of the action's eligible costs

Total costs (including non-EU funded)	Total costs	Maximum grant amount	Forms of costs
3,294,306.01	3,092,400.01	3,092,400.00	Unit, actual, flat rate, unit

Prefinancing and guarantees:

Prefinancing amount	Guarantee fund Amount
1,649,280.00	154,620.00

Bank account (IBAN, BIC) for payments: ES2701825566770201501777

Reporting periods:

No	Month From	Month To
1	1	18
2	19	36
3	37	48

Obligation to keep records (in years): 5

Right to carry out reviews (up to number of years): 2

Right to carry out audits (up to number of years): 2

Extension of audit findings from other grants to this grant (no later than number of years): 2

Evaluation of the impact of the action (up to number of years): 5

List of beneficiaries and linked third parties and international partners:

Beneficiary/linked third party/ international partner	Role	PIC	Full official name	Country	Total cost (including non-EU funded)	Max contrib. rate	Max Grant Amount
1 - SAS	CO	998853621	SERVICIO ANDALUZ DE SALUD	ES	418,783.13	100.00%	418,783.12
FISEVI	LinkTP	994159888	FUNDACION PUBLICA ANDALUZA PARA LAGESTION DE LA INVESTIGACION EN SALUD DE SEVILLA	ES	373,216.88	100.00%	373,216.88
2 - INT	BEN	998538759	FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI	IT	450,000.00	100.00%	450,000.00



Beneficiary/linked (third party/ international partner)	Role	PIG	Full official name	Country	Total costs (including non-EU funded)	Max. contrib. rate	Max Grant Amount
3 - IOR	BEN	999445709	ISTITUTO ORTOPEDICO RIZZOLI	IT	432,000.00	100.00%	432,000.00
4 - CLB	BEN	998171032	CENTRE ANTICANCEREUX LEON BERARD	FR	486,000.00	100.00%	486,000.00
5 - INCAN	BEN	996661227	Instituto Nacional de Cancerologia	MX	306.00		0.00
6 - ACC	BEN	996873560	FUNDACAO ANTONIO PRUDENTE	BR	201,600.00		0.00
7 - IAF	BEN	907186002	ALEXANDER FLEMING SA	AR	194,400.00	100.00%	194,400.00
8 - FUNDAEVI	BEN	904377464	FUNDACION AMOR ESPERANZA Y VIDA	CR	180,000.00	100.00%	180,000.00
9 - INE	BEN	927689571	INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS-INEN	PE	176,400.00	100.00%	176,400.00
10 - GEIS	BEN	951372412	GRUPO ESPANOL DE INVESTIGACION EN SARCOMAS ASOCIACION	ES	306,000.00	100.00%	306,000.00
11 - SPAEN	BEN	964352467	SARCOMA PATIENTS EURONET EV	DE	75,600.00	100.00%	75,600.00

GA options:

- Article 6.2.D.2 – Equipment costs – depreciation
- Article 6.2.D.4 – Large research infrastructure (LRI) costs
- Article 9 – Beneficiaries not receiving EU funding
- Article 9 – NOT coordinator and WITHOUT linked third parties receiving EU funding
- Article 14 – Linked third parties
- Article 29.3 – Actions that participate in the Open Research Data Pilot
- Article 29.3 – Actions that participate in the Open Research Data Pilot
- Article 29.3 – Health actions that participate in the Open Research Data Pilot
- Article 31.5 – Access rights to results for EU – EU grants
- Article 41.2 – Third party with ‘authorisation to administer’
- Article 57.2 – Dispute settlement – non-EU beneficiaries
- Article 57.2 – Dispute settlement – international organisations or non-EU beneficiaries not receiving EU funding that cannot be subject to Belgian courts

If the reports submitted do not comply with this Article, the Commission may suspend the payment deadline (see Article 47) and apply any of the other measures described in Chapter 6.

If the coordinator breaches its obligation to submit the reports and if it fails to comply with this obligation within 30 days following a written reminder, the Commission may terminate the Agreement (see Article 50) or apply any of the other measures described in Chapter 6.

## **ARTICLE 21 — PAYMENTS AND PAYMENT ARRANGEMENTS**

### **21.1 Payments to be made**

The following payments will be made to the coordinator:

- one **pre-financing payment**;
- one or more **interim payments**, on the basis of the request(s) for interim payment (see Article 20), and
- one **payment of the balance**, on the basis of the request for payment of the balance (see Article 20).

### **21.2 Pre-financing payment — Amount — Amount retained for the Guarantee Fund**

The aim of the pre-financing is to provide the beneficiaries with a float.

It remains the property of the EU until the payment of the balance.

The amount of the pre-financing payment will be EUR 1 649 280.00 (one million six hundred and forty nine thousand two hundred and eighty EURO).

The Commission will — except if Article 48 applies — make the pre-financing payment to the coordinator within 30 days, either from the entry into force of the Agreement (see Article 58) or from 10 days before the starting date of the action (see Article 3), whichever is the latest.

An amount of EUR 154 620.00 (one hundred and fifty four thousand six hundred and twenty EURO), corresponding to 5% of the maximum grant amount (see Article 5.1), is retained by the Commission from the pre-financing payment and transferred into the '**Guarantee Fund**'.

### **21.3 Interim payments — Amount — Calculation**

Interim payments reimburse the eligible costs incurred for the implementation of the action during the corresponding reporting periods.

The Commission will pay to the coordinator the amount due as interim payment within 90 days from receiving the periodic report (see Article 20.3), except if Articles 47 or 48 apply.

Payment is subject to the approval of the periodic report. Its approval does not imply recognition of the compliance, authenticity, completeness or correctness of its content.

The **amount due as interim payment** is calculated by the Commission in the following steps:

Step 1 — Application of the reimbursement rates